TG Therapeutics Raises 2024 Revenue Guidance Amid Soaring BRIUMVI Sales
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
- Latest
- Trending
TG Therapeutics' Q2 2024 results show BRIUMVI sales at $72.6M, prompting a revenue guidance raise to $290-$300M.
Explore conflicting analyst opinions on Alnylam's HELIOS-B data, contrasting efficacy views for vutrisiran in addressing ATTR-CM treatments.
"ResMed and Inspire Medical stocks plummet after Eli Lilly's Zepbound trial success; Citi downgrades RMD, sees market shift. Read more ...
"New VR Engineering Research Center in Hainan aims to transform education and industry with AI, featuring innovative tech like virtual ...
"Numinus Wellness acquires MedBright AI, merging AI with psychedelics for advanced mental health care and expanded services in the U.S."
Eli Lilly's Zepbound reduces sleep apnea by up to 52% in trials, showing promise beyond weight loss. FDA approval for ...
"Iontronic tech shows promise in slowing malignant brain tumor growth by continuously delivering low-dose drugs, bypassing the blood-brain barrier."
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Catch up on biotech headlines: Zentalis faces FDA hold, Aerovate's major setback, Merck's new vaccine, and promising trials by Intra-Cellular ...
Discover the booming VRET market, driven by tech advances and mental health needs, expected to grow at a 33.90% CAGR ...
We are building the future together with you. We write content with maximum speed and excellent quality. Each material is accompanied by an analyst's commentary.